[The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin].
Lukash. N V NV; Polishchuk. T F TF; Ludan. V V VV
Key Findings
- Duodenal ulcer patients showed reduced T‑lymphocyte markers (E‑rosette, theophylline‑resistant and theophylline‑sensitive lymphocytes) compared to healthy controls.
- Combined therapy with thymalin and dalargin increased T‑lymphocyte counts and subpopulations to levels similar to those of healthy individuals.
- The percentage of theophylline‑sensitive lymphocytes (TFS‑RFC) did not change before or after treatment.
Practical Outcomes
- Thymalin appears to have an immune‑boosting effect in a specific patient group, suggesting it could help normalize T‑cell numbers when the immune system is compromised. However, the study is limited to duodenal ulcer patients, provides no dosage details, and does not address long‑term safety or benefits for healthy individuals, so biohackers should treat this as preliminary evidence rather than a ready‑to‑use protocol.
Summary
In people with duodenal ulcers, the study found that their immune T‑cell numbers were lower than in healthy folks. Adding the peptide thymalin (together with dalargin) to their treatment helped bring those T‑cell counts back up to normal levels. The effect was specific to certain T‑cell subtypes, while others stayed unchanged.
Abstract
Kept under medical surveillance were 120 patients with duodenal ulcer running an uncomplicated course. All patients and 30 healthy donors were studied for the status of the immunity T-system by spontaneous E-rosette formation (E-RFC) and availability of theophylline-resistant (TPP-RFC) and theophylline-sensitive (TPS-RFC) lymphocytes. With B-system being studied by FAC-rosette formation. All patients with duodenal ulcer displayed a decline in the content of E-RFC, TFP-RFC, TFS-RFC as compared to the indices in controls. Inclusion into the combined therapy of thymalin and dalargin was noted to be associated with a positive dynamics in the rise of T-lymphocytes, their subpopulations to the level in controls, percentage of TFS-RFC. Indices for TFS-RFC did not differ from control ones either before or after the treatment.
Study Information
pubmed
1998